Quininib
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC50s of 1.2 and 52 μM for CysLT1R and CysLT2R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents[1].
Product Specifications
CAS Number
143816-42-6
UNSPSC
12352005
Target
Leukotriene Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/quininib.html
Purity
98.1
Solubility
10 mM in DMSO
Smiles
OC1=CC=CC=C1/C=C/C2=NC3=CC=CC=C3C=C2
Molecular Formula
C17H13NO
Molecular Weight
247.29
References & Citations
[1]Alison L Reynolds, et al. Phenotype-based Discovery of 2-[ (E) -2- (Quinolin-2-yl) vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. J Biol Chem. 2016 Apr 1;291 (14) :7242-55.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
LTC4/CysLT2; LTD4/CysLT1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC683273-100 1x 100 µL
Uroplakin 1B (Urothelial Differentiation Marker) (UPK1B/3273), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details